

Date: 14.11.2018

To,  
B S E Limited,  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Mumbai-400001

**Sub: - Unaudited Financial Result under Regulation 33 of the SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 for the Quarter and half year ended on 30<sup>th</sup> September, 2018**

**Company Scrip Code: 532167**

Dear Sir,

Pursuant to the provisions of Regulation 33 of the SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015, please find enclosed herewith:


1. Unaudited Financial Results of the Company, for the Quarter and half year ended on 30<sup>th</sup> September, 2018, along with Limited Review Report.
2. Statement of Asset and Liability of the Company.

The aforesaid result has been approved by the Board of Directors at their meeting held on 14<sup>th</sup> November, 2018.

This is for your information and record.


Thanking You,

Yours faithfully,  
For **Omkar Pharmachem Limited**

  
(Anurag Sharma)  
Managing Director  
DIN-02289261  
Add: A-727, Sarita Vihar, New Delhi-110076

Encl: a/a

Statement of Unaudited Financial Results for the Quarter and Six Months ended 30th September, 2018						
(Rs. in lakhs except per share data)						
Sr. No.	Particulars	Quarter Ended On			Six Months Ended On	
		30-09-2018	30-06-2018	30-09-2017	30-09-2018	30-09-2017
		(unaudited)	(unaudited)	(unaudited)	(unaudited)	(unaudited)
	<b>Part-I</b>					
1	<b>Income from operations</b>					
	a) Net Sales/ Income from Operations	0.00	0.00	0.00	0.00	0.00
	b) Other Operating Income	0.00	0.00	0.00	0.00	0.00
2	Other Income	0.00	0.00	0.00	0.00	0.00
3	<b>Net Total Income</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>
4	<b>Expenses</b>					
	a) Cost of material consumed	0.00	0.00	0.00	0.00	0.00
	b) Purchase of Stock-in-trade	0.00	0.00	0.00	0.00	0.00
	c) Changes in Inventories of Finished Goods, WIP and Stock-in-trade	0.00	0.00	0.00	0.00	0.00
	d) Employee benefits expenses	7.09	3.51	3.44	10.60	6.87
	e) Finance Cost	0.01	0.01	0.01	0.02	0.05
	f) Depreciation and Amortization Expenses	0.09	0.09	0.04	0.18	0.09
	g) Other Expenses	1.74	5.54	1.57	7.28	6.94
	Total Expenses	8.93	9.15	5.06	18.08	13.95
5	<b>Profit(Loss) from operations before Exceptional Items &amp; Taxes (3-4)</b>	<b>(8.93)</b>	<b>(9.15)</b>	<b>(5.06)</b>	<b>(18.08)</b>	<b>(13.95)</b>
6	Exceptional items:	0.00	0.00	0.00	0.00	0.00
7	<b>Profit(Loss) before Tax (5+6)</b>	<b>(8.93)</b>	<b>(9.15)</b>	<b>(5.06)</b>	<b>(18.08)</b>	<b>(13.95)</b>
8	Tax Expense	0.00	0.00	0.00	0.00	0.31
9	<b>Profit(Loss) for the period (7-8)</b>	<b>(8.93)</b>	<b>(9.15)</b>	<b>(5.06)</b>	<b>(18.08)</b>	<b>(13.95)</b>
10	Other Comprehensive Income (Expense)	0.00	0.00	0.00	0.00	0.00
11	<b>Total Comprehensive Income for the period (9+10)</b>	<b>(8.93)</b>	<b>(9.15)</b>	<b>(5.06)</b>	<b>(18.08)</b>	<b>(13.95)</b>
12	<b>Paid up Equity Share Capital (Face Value Rs. 10/- each)</b>	<b>1008.37</b>	<b>1008.37</b>	<b>1008.37</b>	<b>1008.37</b>	<b>1008.37</b>
13	<b>Reserves excluding Revaluation Reserves as on 31st March</b>	<b>(96.26)</b>	<b>(96.26)</b>	<b>(70.65)</b>	<b>(96.26)</b>	<b>(70.65)</b>
14	<b>Earning Per Share(before &amp; after extraordinary items)(of Rs. 10 each)(not annualised) Basic and diluted Rs</b>	<b>(0.0886)</b>	<b>(0.0907)</b>	<b>(0.0502)</b>	<b>(0.1793)</b>	<b>(0.1383)</b>



Statement of Assets and Liabilities		(Rs. in lakhs)	
Sr. No	Particulars	As at 30-09-2018 (Unaudited)	As at 31-03-2018 (Audited)
	<b>ASSETS</b>		
	Non-current Assets		
	a) Property, plant and equipment	0.47	0.65
	b) Capital work-in-progress	0.00	0.00
	c) Goodwill on consolidation	0.00	0.00
	d) Other intangible assets	0.00	0.00
	e) Intangible assets under development	0.00	0.00
	f) Financial assets	0.00	0.00
	i) Investments		
	a) Investment in associate	0.00	0.00
	b) Investments in joint ventures	0.00	0.00
	c) Other Investments	930.00	930.00
	ii) Other Financial Assets	0.00	0.00
	g) Deferred tax assets (net)	0.02	0.02
	h) Other non current assets	0.18	0.18
	<b>Total Non-current Assets</b>	<b>930.67</b>	<b>930.85</b>
	Current Assets		
	a) Inventories	0.00	0.00
	b) Financial assets		
	i) Other Investments	0.00	0.00
	ii) Trade receivables	7.46	7.46
	iii) Cash and cash equivalents	2.05	2.02
	iv) Bank balances other than iii) above	0.00	0.00
	v) Other financial assets	0.00	0.00
	c) Other current assets	0.00	0.00
	<b>Total Current Assets</b>	<b>9.51</b>	<b>9.48</b>
	<b>Total Assets</b>	<b>940.18</b>	<b>940.33</b>
	<b>EQUITY AND LIABILITIES</b>		
	<b>Equity</b>		
	a) Equity share capital	1008.37	1008.37
	b) Other equity - Reserve and Surplus	-114.34	-96.26
	Equity attributable to the owners of the company	894.03	912.11
	Non-controlling interests	0.00	0.00
	<b>Total Equity</b>	<b>894.03</b>	<b>912.11</b>
	<b>Non-current liabilities</b>		
	Financial liabilities		
	a) Borrowings	0.00	0.00
	b) Provisions	0.00	0.00
	c) Deferred tax liabilities(Net)	0.00	0.00
	<b>Total Non-current Liabilities</b>	<b>0.00</b>	<b>0.00</b>
	<b>Current Liabilities</b>		
	a) Financial liabilities		
	i) Borrowings	42.18	24.18
	ii) Trade Payables	2.13	1.89
	iii) Other financial liabilities	1.38	1.43
	b) Provisions	0.44	0.44
	c) Other current liabilities	0.02	0.28
	<b>Total-current Liabilities</b>	<b>46.15</b>	<b>28.22</b>
	<b>Total Liabilities</b>	<b>46.15</b>	<b>28.22</b>
	<b>Total Equity and Liabilities</b>	<b>940.18</b>	<b>940.33</b>

Notes:

- The above results have been reviewed by the audit committee & approved by the Board of Directors at the respective meeting held on 14-11-2018
- Corresponding previous period figures are regrouped/rearranged wherever necessary, to make them comparable
- The financial result for the Quarter and Half yearly ended on 30-09-2018 has been prepared in accordance with the IND-AS specified under section 133 of the companies Act and rules made thereunder.
- The IND-AS regarding segment reporting is not applicable to the company as there is no segment.

By order of the Board

  
(Anurag Sharma)

Managing Director  
DIN: 02289261

A-727, Savita Vihar, New Delhi 110076

Date: 14-11-2018  
Place: Ahmedabad





Limited review report to The Board of Directors of Omkar Pharmachem Limited for quarter and half year ended on 30<sup>th</sup> September, 2018

We have reviewed the accompanying statement of unaudited financial results of Omkar Pharmachem Limited for the quarter and half year ended on 30<sup>th</sup> September, 2018. This statement is the responsibility of the Company's management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.


We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and; thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our notice that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards i.e. Indian Accounting Standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Ahmedabad  
Date : 14/11/2018



For Rajesh J. Shah & Associates  
Chartered Accountants  
ERN 108407W

  
(Rajesh J. Shah)  
Partner